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Background: Though documented that HIV infection progresses with the depletion of CD4+ cells, the exact
mechanisms by which these cell depletions occur are not clearly understood. This study aimed at evaluating the
plasma levels of soluble Fas receptors and ligands in HIV-infected and uninfected patients in Yaounde, Cameroon, a
population with a known diversity of HIV in whom this has not been previously assessed.
Findings: In a cross-sectional study, 39 antiretroviral naïve HIV-1 positive and negative participants were recruited in
Yaounde, Cameroon. CD4+ lymphocyte cell counts were quantified from whole blood using an automated
FACScount machine (Becton-Dickinson, Belgium). Plasma samples obtained were analyzed for soluble Fas receptors
and Fas ligands in both HIV-1 positive and negative samples using two different quantitative sandwich ELISA kits
(QuantikineW, R&D Systems , UK).
Plasma levels of Fas receptors were higher in HIV-1 positive patients (median = 1486pg/ml IQR = 1193, 1830pg/ml)
compared to HIV-negative controls (median = 1244pg/ml, IQR = 1109, 1325pg/ml), p-value <0.001. Plasma levels of
Fas ligands were also higher in HIV-1 positive patients (median = 154pg/ml, IQR = 111, 203pg/ml) compared to HIV-
negative controls (median = 51pg/ml, IQR = 32, 88pg/ml), p-value = 0.005. Plasma concentrations of soluble fas
receptors and ligands tended to be negatively correlated with the CD4+ cell counts of HIV-positive patients; the
correlation coefficients were -0.34 (value = 0.78) and-0.3 (p-value = 0.51) respectively.
Conclusions: In this population of patients in Cameroon, plasma concentrations of Fas receptors and Fas ligands
tend to be higher in HIV-positive patients. The Fas pathway of apoptosis may have a role in the depletion of CD4+
cell counts
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Background
Infection with human immunodeficiency virus type 1
(HIV-1) is characterised by a gradual and progressive
CD4+ T-helper cell depletion [1]. The Fas mediated
mechanism of apoptosis during activation induced cell
death (AICD) system is a key regulator of apoptosis in* Correspondence: gikomey@yahoo.com
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reproduction in any medium, provided the ornormal and malignant T cells [2,3]. Many studies have
shown that the mechanism of T-cell receptor(TCR)-trig-
gered activated induce cell death (AICD) in peripheral
T-cell mediated via CD95 receptor/ligand interaction are
up regulated and involved in this loss of CD4+ cells in
HIV-1 infected patients[2,4]. All T-lymphocytes cells ex-
press the CD95 cell-surface receptor, a member of the
TNF-R/NGT-R super family, which can induce apoptosis
upon oligomerization with its ligand, resulting to CD4+
T-cell death [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1756-0500/5/322In spite of these, the exact mechanisms by which these
cell depletions occur are not clearly understood. Sec-
ondly it is not known if these mechanisms are univer-
sally similar irrespective of study population or viral
type.
In this study we evaluated the plasma concentration of
soluble Fas receptors and ligands in HIV-positive patients
and compared them to HIV-negative controls. We also

































































Figure 1 Plasma concentration of Fas receptors (top panel) and Fas li
Yaounde, Cameroon. The middle horizontal lines represent the median cof each of Fas receptors and ligands with CD4+ lympho-
cyte cell counts in HIV-1 positive patients in Cameroon, a
population with a known diversity of HIV-1 in which
these pathways have not been previously assessed.
Methods
This study was reviewed and approved by Faculty of




gands (bottom panel) by HIV-1 status in 39 participants in
oncentrations of Fas ligands or Fas receptors.
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http://www.biomedcentral.com/1756-0500/5/322Thirty-nine antiretroviral naïve HIV-1 positive and
negative participants were recruited from the Centre for
the Study and Control of Communicable Diseases
(CSCCD) of the Faculty of Medicine and Biomedical
Sciences in Yaoundé, Cameroon. After obtaining written
consent, demographic data were recorded from each
participant using a standardized questionnaire. Ten ml
of blood was collected in EDTA anticoagulant tubes
from each participant. The blood was then centrifuged
at 12000rpm for five minutes and plasma separated and
stored in two vials of 1.5ml each. The plasma was then
analyzed for Fas receptor (CD95) and Fas ligands
(CD95L) in both HIV-1 positive and negative samples
using two different quantitative sandwich ELISA kits
(QuantikineW, R&D Systems , UK). All samples were
analysed based on the manufacturers’ guidelines. It is
worth noting that this assays will detect any Fas ligands
(or receptors) present in plasma and thus the sensitivity
is not expected to be reduced because of the presence of
receptor-ligand complexes.
Data were entered into a Microsoft Excel spreadsheet
and analysed using STATA version 8 (STATA Corps
Texas USA). Plasma levels of Fas receptor and Fas
ligands levels in HIV positive and negative participants
were compared using the Mann-Whitney U-Test. A
spearman rank correlation coefficient was used to deter-

































Figure 2 Correlation between plasma levels of Fas receptors and Fas
individual observations and the straight line is the line of best fit.Fas ligands with CD4+ cell counts. These data are avail-
able, upon request, from the corresponding author.
Results
Of the 39 participants , 19 (49%) were females and 27
(69%) were HIV-1 seropositive. Plasma levels of Fas
receptors were higher in HIV-1 positive subjects with
(median = 1486pg/ml, IQR= 1193, 1830pg/ml) compared
to HIV-1 negative subjects (median = 1244pg/ml, IQR=
1109, 1325pg/ml) with a p-value of 0.005 (Figure 1).
The levels of ligands in HIV-positive subjects (median =
154pg/ml, IQR= 111, 203pg/ml) were also higher com-
pared to that in HIV-negative subjects (median = 51pg/
ml, IQR= 32, 88pg/ml) with a p-value = 0.001(Figure 1).
There was a weak correlation between plasma concen-
trations of Fas receptors and Fas ligands with a Spear-
man correlation coefficient of 0.32.(Figure 2).
Plasma concentrations of soluble Fas receptors and
ligands were negatively (though not statistically signifi-
cantly) correlated with the CD4+ cell counts of HIV-
positive patients: the correlation coefficients were -0.34
(p-value = 0.78) and -0.3 (p-value = 0.51) respectively
(Figure 3).
Discussion
This study aimed at evaluating the plasma concentra-
tions of soluble Fas receptors and ligands in relation to200 300
AS Ligands(pg/ml)


































































Figure 3 Correlation between CD4+ cell counts and plasma levels of each of Fas receptors (upper panel) and Fas ligands (lower panel)
in 27 HIV-positive participants in Yaounde, Cameroon. For each panel, the dots are the individual observations and the straight line is the
line of best fit.
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http://www.biomedcentral.com/1756-0500/5/322CD4+ cell depletion in a population with high HIV-1
genetic diversity. Our results show an increase in the
levels of Fas receptors and ligands in HIV-1 positive
patients compared to HIV-negative subjects. Some pre-
vious studies described an increase in Fas receptor ex-
pression in T-cells from HIV-1 infected children and
adults [3-7]. In a similar study it was also shown that the
membrane-bound Fas levels were higher in lymphocytes
of HIV-1 positive compared to HIV-negative patients; an
increase explained as resulting from a reduction in the
pressure mounted on the normal immune system of
HIV-uninfected cells when compared to infected cells
[8-11]. The increase in Fas receptors and ligands in
HIV-1 infected patients could be in concordance with
Fas ligand shedding during T-cell activations, as most T-
cells are under pressure from the virus [4].We also found a depletion of the levels of CD4+ with
increased Fas ligands and Fas receptors though this was
not statistically significant.
While this study is strengthened by the inclusion of sam-
ples from Cameroon, with high HIV diversity, some limita-
tions need to be considered. The relatively small sample
size may have lowered the power to identify significant cor-
relations between the Fas Ligands and CD4 counts. We did
not analyze the correlation with viral load and HIV subtype.
The cross-sectional nature of the study did not allow for
establishing whether the time relationship between Fas
ligands, the receptors and CD4+ lymphocyte accounts.
Conclusions
Plasma concentration of Fas receptors and Fas ligand,
could be involved in the decrease in CD4+ cells in HIV-
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http://www.biomedcentral.com/1756-0500/5/3221 patients. Further studies on the role of the Fas com-
plex in HIV pathogenesis in this population with signifi-
cant viral diversity are needed. These studies would
assess the potential role of FAS ligands and receptors as
indicators of disease progression and or response to
antiretroviral therapy.
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